Alvartis Pharma

What Alvartis Pharma does

Alvartis Pharma S.A. de C.V. is a 100% Mexican biopharmaceutical company founded in 2002 that develops, manufactures, and commercializes generic and biocomparable specialized medications for the domestic Mexican market. The company's product portfolio spans five therapeutic categories — anesthetics, ophthalmics, nebulization, injectables, and ancillary hospital preparations — with more than 20 branded SKUs (including NOCLORAPIN, VALFOPROX, VAPRINEXT, DEMESYNT, ROBULVAR, SOLVARIS, ALFASINA, LUBALVAR, TRALUB, EXBRUNT, DINITRYL, RETALVAR, FLUFENAX, HAITRAX, RIVOCILVAR, FALVIN, ALVOLDEN, ALVARCIN, FUZITRAN, ANFAKAIR, and CEPTYL) covering anesthetics, antibiotics, antivirals, antifungals, antiarrhythmics, tocolytics, and ophthalmic therapies. The company is positioning toward higher-complexity biotechnological drugs such as therapeutic proteins and monoclonal antibodies.

Manufacturing is concentrated at an 8,280 m² facility in Jaltepec, State of Mexico, operating under COFEPRIS Good Manufacturing Practices certification, Sanitary License, and ISO-9001 Quality Management System certification. The company runs a dedicated pharmacovigilance unit compliant with NOM-220-SSA1-2016 and has built an integrated anesthesia service (Servicio Integral de Anestesia con TIVA) that bundles TCI infusers, depth-of-anesthesia monitors, and neuromuscular relaxation monitors with preventive/corrective maintenance by in-house biomedical engineers.

Revenue is generated through direct sales to two distinct customer segments: private healthcare providers (Ventas Privado) and Mexican government health institutions (Ventas Gobierno), each with dedicated sales contacts, email channels, and phone extensions. Distribution is exclusively domestic within Mexico. The company maintains strategic R&D alliances with three top-tier Mexican universities (UNAM, IPN, UAEM) supporting workforce development and pipeline innovation. Alvartis Pharma is a private corporation (S.A. de C.V.) with no disclosed funding rounds, M&A activity, or parent-company ownership; financial scale is not publicly disclosed.

Name

Alvartis Pharma

Legal name

ALVARTIS PHARMA, S.A. DE C.V.

Website

https://alvartispharma.com.mx

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

Alvartis Pharma is a 100% Mexican biopharmaceutical manufacturer, founded in 2002, producing generic and biocomparable medications across anesthetics, ophthalmic, nebulization, and injectable categories. It serves private hospitals and the Mexican public health sector through dedicated direct-sales channels and operates a COFEPRIS GMP-certified plant in Jaltepec.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Sterile Injectable Generics (HLAIABAC), Generic Hospital & Institutional Products (HLAIABAL), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Generic pharmaceuticals
• Biocomparable medications
• Pharmaceutical manufacturing
• Anesthesia services
• Injectable medications

Headquarters

HQ city

Coyoacán

HQ country

Mexico

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Alvartis Pharma generates revenue through the manufacture and sale of generic and biocomparable pharmaceutical products across five categories: anesthetics, ophthalmic, nebulization, injectables, and nebulization products. The company sells to both private healthcare providers and government institutions (sector salud mexicano).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Alvartis Pharma manufactures and distributes generic and biocomparable pharmaceutical products in Mexico across five therapeutic categories: anesthetics, ophthalmic, nebulization, and injectables. The company operates a 8,280 sq meter COFEPRIS GMP-certified manufacturing plant in Jaltepec, Estado de México, and also offers an Integrated Anesthesia Service (Servicio Integral de Anestesia con TIVA) supplying equipment, consumables, and biomedical engineering maintenance to hospital operating rooms.

Product overview

Alvartis Pharma is a 100% Mexican biopharmaceutical company offering a diverse portfolio of generic and biocomparable medications. Their product portfolio spans across five main categories: Anesthetics (including NOCLORAPIN/Ropivacaína, VALFOPROX/Propofol, VAPRINEXT/Bupivacaína, DEMESYNT/Dexmedetomidina, and ROBULVAR/Bromuro de Rocuronio), Ophthalmic products (SOLVARIS/Cloranfenicol, ALFASINA/Nafazolina, LUBALVAR/Hipromelosa, and TRALUB/Travoprost), Nebulization therapy (EXBRUNT/Bromuro de Ipratropio), and Injectable medications (DINITRYL/Hidralazina, RETALVAR/Atosiban, FLUFENAX/Etofenamato, HAITRAX/Omeprazol, RIVOCILVAR/Aciclovir, FALVIN/Amifostina, ALVOLDEN/Adenosina, ALVARCIN/Vancomicina, FUZITRAN/Caspofungina, ANFAKAIR/Amfotericina B, CEPTYL/Ganciclovir). Additionally, the company offers the Servicio Integral de Anestesia con TIVA, a comprehensive anesthesia service that provides equipment, maintenance, and supplies for operating room anesthesia delivery.

Differentiator

Problem solved

Functional benefit

Brands

• NOCLORAPIN: Anesthetic product - Ropivacaína 150 mg/20 mL and Ropivacaína 40 mg/20 mL
• VALFOPROX
• VAPRINEXT
• DEMESYNT
• ROBULVAR
• SOLVARIS
• ALFASINA
• LUBALVAR
• TRALUB
• EXBRUNT
• DINITRYL
• RETALVAR
• FLUFENAX
• HAITRAX
• RIVOCILVAR
• FALVIN
• ALVOLDEN
• ALVARCIN
• FUZITRAN
• ANFAKAIR
• CEPTYL

Products and services

• NOCLORAPIN (Ropivacaína)
• VALFOPROX (Propofol)
• VAPRINEXT (Bupivacaína)
• DEMESYNT (Dexmedetomidina)
• ROBULVAR (Bromuro de Rocuronio)
• SOLVARIS (Cloranfenicol)
• ALFASINA (Nafazolina)
• LUBALVAR (Hipromelosa)
• TRALUB (Travoprost)
• EXBRUNT (Bromuro de Ipratropio)
• DINITRYL (Hidralazina)
• RETALVAR (Atosiban)
• FLUFENAX (Etofenamato)
• HAITRAX (Omeprazol)
• RIVOCILVAR (Aciclovir)
• FALVIN (Amifostina)
• ALVOLDEN (Adenosina)
• ALVARCIN (Vancomicina)
• FUZITRAN (Caspofungina)
• ANFAKAIR (Amfotericina B)
• CEPTYL (Ganciclovir)
• Servicio Integral de Anestesia con TIVA

Quantifiable outcome

• ISO-9001 certified Quality Management System ensuring compliance with requirements focused on continuous improvement of the SGC and risk management.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Universidad Nacional Autónoma de México (UNAM)coreStrategic or Co-development PartnerAlvartis Pharma has established alliances with UNAM to develop therapeutic medications in collaboration with the university, supporting the development of Mexican scientific talent and contributing to the training of human resources for industrial pharmaceutical production.
• Instituto Politécnico Nacional (IPN)coreStrategic or Co-development PartnerStrategic partnership with IPN for the development of biomedicines and therapeutic medications, supporting Mexican scientific talent development and contributing to workforce training for the biopharmaceutical industry.
• Universidad Autónoma del Estado de Morelos (UAEM)coreStrategic or Co-development PartnerCollaboration with UAEM for the development of accessible biomedicines and therapeutic medications, supporting talent development of future scientists and contributing to the incorporation of biomedicines at accessible prices with high quality standards.

Scale indicators3 records

Recent moves6 records

Direct peers

• Laboratorios Sanfer: Mexican pharmaceutical group with a large generics portfolio spanning multiple therapeutic areas and strong presence in both private and institutional channels. Comparable as a domestic competitor targeting the same hospital and government customer segments.
• Laboratorios Liomont: Established Mexican generic pharmaceutical manufacturer with a broad hospital and retail portfolio, including injectables and specialty products. Comparable to Alvartis in scale, product breadth, and Mexican market focus on institutional buyers.
• PiSA Farmacéutica: One of Mexico's largest pharmaceutical manufacturers, producing generics, injectables, and hospital products across multiple therapeutic categories. Directly comparable to Alvartis as a domestic manufacturer serving both private and government healthcare channels.
• Asofarma: Mexican pharmaceutical manufacturer focused on specialty and institutional products, including hospital injectables. Comparable to Alvartis in serving specialty-care physicians and Mexican hospital systems with branded generics.
• Probiomed: Mexican biopharmaceutical company specializing in biocomparable and biosimilar products, directly comparable to Alvartis's high-specialty biotechnology positioning. Both target the Mexican public and private healthcare sectors with biotech alternatives to imported biologics.
• Laboratorios Grin: Mexican pharmaceutical company focused on ophthalmology products, overlapping directly with Alvartis's ophthalmic portfolio (SOLVARIS, ALFASINA, LUBALVAR, TRALUB). Comparable niche focus and Mexican market specialization.

Broad incumbents

• Genomma Lab Internacional: Large Mexican pharmaceutical company with a broad portfolio across generics, OTC, and personal care. While broader and more retail-focused than Alvartis, it competes for shelf and institutional space in the Mexican generics market.
• Teva Pharmaceutical (Mexico operations): Global generics leader with significant operations in Mexico across injectables, anesthetics, and hospital products. Directly competes with Alvartis in the generic injectables and anesthesia categories but at much greater scale and with broader geographic reach.
• Sandoz (Mexico operations): Global generics and biosimilars division with established presence in Mexico, competing in generic injectables and specialty pharmaceuticals. Comparable as a generics and biosimilars competitor with stronger international backing.

Regional players

• Cristália (LatAm exporter): Brazilian pharmaceutical manufacturer specializing in anesthetics, injectables, and hospital products — a directly comparable product mix to Alvartis. While primarily Brazil-based, it represents the type of regional specialty-generics player that could compete with Alvartis in cross-border institutional tenders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/alvartispharma
• Facebookfacebook.com/AlvartisPharma
• LinkedInlinkedin.com/company/alvartis-pharma-s-a-de-c-v

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvartis Pharma